New research led by a St. Michael’s Hospital clinician-scientist and published in the prestigious New England Journal of ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed.

EDSS score‡ 5.5±1.0 5.6±0.9 Time since onset of symptoms of relapsing–remitting multiple sclerosis — yr 17.1±8.3 17.6±8.4 Time since diagnosis of secondary progressive multiple sclerosis ...

Ocrevus appears to be a safe and effective treatment for children and adolescents with MS, according to real-world data from ...

Researchers still don’t fully understand the cause of multiple sclerosis or why the rate of progression is so difficult to ...

Cognitive symptoms, mood disorders, and fatigue manifest differently in relapsing-remitting vs. progressive forms of MS, a ...

Prof Jeremy Chataway, consultant neurologist at the National Hospital for Neurology and Neurosurgery in London, who is ...

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral ...